Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascorbic Acid and Temozolomide for Recurrent High Grade Glioma
NCT02168270Phase 1Terminated
- Sponsor
- University of Nebraska
- Start
- Jun 2014
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ascorbic acid in high-grade glioma (HGG), sponsored by University of Nebraska. Primary endpoints: Maximum Tolerated Dose of Ascorbic Acid in Combination With Temozolomide at 56 days and Incidence Rates of Adverse Events. Started Jun 2014; status: terminated.
02
Drugs
ascorbic acid
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02168270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168270.